Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Ypsomed
MyLife Diabetes Care completes transition to independent company
MyLife Diabetes Care announced that its transition into an independent company has now been formally completed. In August, Ypsomed announced that it completed the sale of its diabetes care business to TecMed AG. With this sale, the company transitioned MyLife from a business unit into a standalone company. This follows a recent medtech trend, with […]
BD, Ypsomed to develop new syringe for biologics
BD (NYSE: BDX) and Ypsomed recently announced they will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass prefillable syringe. The new BD syringe is presently in development and will undergo comprehensive testing to ensure its compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform. Syringe samples for feasibility studies […]
Ypsomed launches YpsoLoop autoinjector platform designed for circularity
Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]
Ypsomed to open first U.S. manufacturing plant in North Carolina
Ypsomed (SIX:YPSN) announced today that it plans to establish its first manufacturing facility in the U.S. The Swiss drug delivery device maker selected Holly Springs, North Carolina for the location. It plans to invest approximately $249.5 million (CHF 200 million) in the first phase of the plant. It expects the Holy Springs site to supply […]
Ypsomed gets FDA nod for digital add-on for autoinjectors
Ypsomed announced that the FDA granted 510(k) clearance for SmartPilot, a digital connectivity add-on for its Ypsomate autoinjectors. The device transforms the YpsoMate into a connected system that automatically captures and transmits injection data. Ypsomed said this marks an important step toward digital health solutions that offer deeper insight into therapy use. The digital add-on […]
Ypsomed completes sale of diabetes care business to TecMed
Ypsomed announced today that it successfully completed the sale of its diabetes care business to TecMed AG. Burgdorf, Switzerland–based Ypsomed in April announced its plans to sell the business to help focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
The 10 largest diabetes technology companies in the world
What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its auto-injector. The Chinese National Medical Products Administration (NMPA) approved Maxdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Innovent Biologics. It treats people with obesity through delivery with an YpsoMate 1.0 auto-injector variant. YpsoMate, a user-friendly […]
Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
Ypsomed and CamDiab announced today that they agreed to integrate their mylife Loop automated insulin delivery system with a future Abbott (NYSE:ABT) sensor. The companies plan to pair their pump system with the Abbott dual glucose-ketone sensor, currently under development. Ypsomed and CamDiab join three other companies set to pair their pumps with the sensor after Abbott recently […]
